financetom
Business
financetom
/
Business
/
Hims & Hers Health Unusual Options Activity For August 13
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Hims & Hers Health Unusual Options Activity For August 13
Aug 13, 2024 9:06 AM

Financial giants have made a conspicuous bearish move on Hims & Hers Health ( HIMS ). Our analysis of options history for Hims & Hers Health ( HIMS ) revealed 8 unusual trades.

Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $313,000, and 4 were calls, valued at $186,050.

Predicted Price Range

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $11.0 and $30.0 for Hims & Hers Health ( HIMS ), spanning the last three months.

Analyzing Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Hims & Hers Health ( HIMS ) options trades today is 839.57 with a total volume of 4,821.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Hims & Hers Health's ( HIMS ) big money trades within a strike price range of $11.0 to $30.0 over the last 30 days.

Hims & Hers Health Option Volume And Open Interest Over Last 30 Days

Biggest Options Spotted:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
HIMS PUT SWEEP BEARISH 01/17/25 $0.85 $0.8 $0.84 $11.00 $117.8K 142 3.0K
HIMS PUT SWEEP BEARISH 01/17/25 $5.4 $5.1 $5.4 $20.00 $107.9K 653 200
HIMS CALL TRADE BULLISH 07/18/25 $3.4 $3.3 $3.4 $20.00 $55.0K 753 162
HIMS CALL TRADE BEARISH 01/16/26 $2.65 $2.6 $2.6 $30.00 $52.0K 991 208
HIMS PUT SWEEP BEARISH 01/17/25 $2.35 $2.3 $2.35 $15.00 $47.0K 1.6K 900

About Hims & Hers Health

Hims & Hers Health Inc ( HIMS ) is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.

In light of the recent options history for Hims & Hers Health ( HIMS ), it's now appropriate to focus on the company itself. We aim to explore its current performance.

Where Is Hims & Hers Health Standing Right Now?

With a trading volume of 3,006,014, the price of HIMS is up by 1.31%, reaching $16.18.

Current RSI values indicate that the stock is may be oversold.

Next earnings report is scheduled for 83 days from now.

What The Experts Say On Hims & Hers Health

A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $21.333333333333332.

Maintaining their stance, an analyst from Truist Securities continues to hold a Hold rating for Hims & Hers Health ( HIMS ), targeting a price of $23.

An analyst from Deutsche Bank has decided to maintain their Hold rating on Hims & Hers Health ( HIMS ), which currently sits at a price target of $23.

An analyst from Piper Sandler has revised its rating downward to Neutral, adjusting the price target to $18.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Hims & Hers Health ( HIMS ) options trades with real-time alerts from Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock
Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock
Jul 11, 2025
Capricor Therapeutics Inc. ( CAPR ) stock is trading lower on Friday. The company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Deramiocel, the company’s lead cell therapy candidate for cardiomyopathy associated with Duchenne muscular dystrophy (DMD). In the CRL, the FDA stated that it had completed...
BMW CEO hopeful for 'manageable' deal on US auto import tariffs
BMW CEO hopeful for 'manageable' deal on US auto import tariffs
Jul 11, 2025
MUNICH (Reuters) -BMW's CEO said on Friday he was optimistic that the European Union and the United States would soon reach a manageable agreement on auto import tariffs, potentially including a mechanism to offset imports with exports. Oliver Zipse's comments come as Europe awaits a letter from the U.S. administration under Donald Trump that could outline the framework of a...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
BMW CEO hopeful for 'manageable' deal on US auto import tariffs
BMW CEO hopeful for 'manageable' deal on US auto import tariffs
Jul 11, 2025
MUNICH, July 11 (Reuters) - BMW's CEO said on Friday he was optimistic that the European Union and the United States would soon reach a manageable agreement on auto import tariffs, potentially including a mechanism to offset imports with exports. Oliver Zipse's comments come as Europe awaits a letter from the U.S. administration under Donald Trump that could outline the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved